May 16th 2024
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Pegylated Liposomal Doxorubicin Being Reconsidered in Relapsed Ovarian Cancer
July 2nd 2002LEICESTER, England-Pegylated liposomal doxorubicin (Doxil/Caelyx) performs as well as paclitaxel (Taxol) in the treatment of relapsed ovarian cancer, according to a clinical trial that was stopped when paclitaxel won approval for first-line treatment in Europe. The trial was nearly forgotten, but then a second look at the results suggested that pegylated liposomal doxorubicin might be preferred for some patients who have musculoskeletal disorders or are troubled by the prospect of developing alopecia as a side effect (ASCO abstract 808).
Intraperitoneal Regimen Boosts Survival in Phase III Ovarian Cancer Clinical Trial
July 1st 2002BALTIMORE-Giving paclitaxel (Taxol) and cisplatin (Platinol) in an intensive intraperitoneal (IP) regimen increased progression-free survival by 5 months over standard intravenous (IV) treatment for stage III epithelial ovarian carcinoma and primary peritoneal carcinoma in a phase III clinical trial (ASCO abstract 803).
Doxorubicin/Cisplatin/Paclitaxel Regimen Improves Survival in Endometrial Cancer
July 1st 2002CHICAGO-Adding paclitaxel (Taxol) and G-CSF support to the standard regimen of doxorubicin and cisplatin (Platinol) improved response rates and increased survival by about 3 months for patients with advanced or recurrent endometrial cancer in a randomized controlled phase III trial conducted by the Gynecologic Oncology Group (GOG) (ASCO abstract 807).
Side Effects of the Treatment of Ovarian Cancer Can Have Great Impact on Activities of Daily Living
June 1st 2002NEW YORK-Treatment of ovarian cancer can cause side effects that have a significant impact on patients’ everyday lives, including walking, according to Lois Almadrones, RN, MS, MPA, clinical nurse specialist, Gynecology Service, Memorial Sloan-Kettering Cancer Center in New York. Speaking at an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting, she outlined approaches to improve the management of palmar-plantar erythrodysesthesia (PPE), peripheral neuropathy, and hypersensitivity to some chemotherapeutic agents.
High-Risk Hispanics Interested in Genetic Testing for Breast Cancer
June 1st 2002WASHINGTON-A survey of 110 Hispanic women at elevated risk for breast and/or ovarian cancer revealed a high degree of interest in genetic testing but a low level of knowledge about their own objective risk of getting these cancers, Martha P. Martinez, PsyD, said at the American Psychological Association Conference on Enhancing Outcomes in Women’s Health. Dr. Martinez is a voluntary instructor of medicine at the University of Miami School of Medicine.
Quality of Life Becomes More Important
June 1st 2002DALLAS-With "significant improvement" in both progression-free and 5-year survival of patients with ovarian cancer, "quality of life becomes important," stated Alan N. Gordon, MD, director of research in gynecologic oncology in the Division of Oncology at Texas Oncology in Dallas.
Haptoglobin-Alpha, Potential Marker for Ovarian Cancer, Identified
June 1st 2002SAN FRANCISCO-Haptoglobin-alpha, a subunit of the hemoglobin-binding protein haptoglobin, may be a useful marker for ovarian cancer, according to results presented at the 93rd Annual Meeting of the American Association for Cancer Research (abstract 3687).
At Each Phase, Patients—and Their Oncology Nurses—Face Distinct Challenges
June 1st 2002TORONTO-Beyond its physical effects, ovarian cancer presents women with difficult emotional, social, and spiritual challenges every step of the way. Each of the disease’s phases, from the first suspicions of something seriously wrong, through diagnosis, treatment, survival, possible relapse, and terminal disease, has its own particular psychosocial impact and its own set of needs, said Margaret I. Fitch, RN, PhD, at an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting.
Docetaxel in the Treatment of Ovarian Cancer
June 1st 2002Docetaxel (Taxotere) has extended the armamentarium of agents with significant activity in the treatment of ovarian cancer. As a single agent in advanced ovarian cancer patients previously treated with a platinum agent, docetaxel at 100 mg/m² every 3 weeks yields a 30% overall response rate and a 6-month duration of response.
The Current Status of Docetaxel in Solid Tumors
June 1st 2002In less than a decade, docetaxel (Taxotere) has progressed from initial studies in anthracycline-refractory metastatic breast cancer to several large, phase III randomized trials evaluating its efficacy as adjuvant, neoadjuvant, and first-line therapy for metastatic breast cancer, non-small-cell lung cancer (NSCLC), and ovarian cancer. In other tumor types, including prostate, head and neck, gastric, and bladder cancer, ongoing phase III trials are comparing docetaxel-containing regimens to previously established regimens. For the seven tumor types reviewed in this supplement, phase III study information for docetaxel or docetaxel-based combinations are presented. Impressive results have been consistently demonstrated in the trials reported to date.
Patients and Their Caregivers Learn to Live in the Moment
June 1st 2002WASHINGTON, DC-"On the day that changed my life, I heard the words, ‘Congratulations! It’s a girl!’ followed by, ‘Oh, no-this is advanced ovarian cancer," Joan Sommer, RN, recalled. "I kept thinking, Baby? Cancer? Baby? Cancer? How can this be?"
Irinotecan and Other Agents in Upper Gastrointestinal and Genitourinary Tumors
May 2nd 2002The 4th Investigators’ Workshop sponsored by The University of Texas M. D. Anderson Cancer Center was held on July 25-29, 2001, in Colorado Springs, Colorado. The purpose of these annual workshops has been to review the latest data on new agents, with a particular focus on the broadly used agent irinotecan (CPT-11, Camptosar).
Irinotecan in Epithelial Ovarian Cancer
May 2nd 2002Ovarian cancer, the second most common gynecologic malignancy, accounts for approximately 14,000 deaths annually in the United States. Disease relapse after primary treatment, which consists mainly of surgery followed by platinum-based therapy, occurs in more than 60% of ovarian cancer patients overall, and in more than 80% of those diagnosed initially with advanced-stage disease.
Irinotecan and Gemcitabine in Patients With Solid Tumors: Phase I Trial
Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m² IV. In this phase I trial, the maximum tolerated dose was defined as the dose level immediately below the level in which two of the first three patients in any cohort, or at least two of six patients in any expanded cohort, experienced dose-limiting toxicity. Dose-limiting toxicity pertained only to toxicity during the first cycle of treatment. Escalation of irinotecan was planned in groups of three patients, with three additional patients added at the first indication of dose-limiting toxicity. A total of 19 patients have been enrolled.
Cancer Signatures Promise Better Detection, Staging, Treatment
May 1st 2002BETHESDA, Maryland-As researchers probe the complex nature of individual cancer cells, unique molecular patterns, or signatures, have emerged. Several drugs based on early findings in the field have already earned US Food and Drug Administration approval. A goal set by the National Cancer Institute (NCI) is to "catalog distinguishing molecular signatures of cancer cells to develop new diagnostic and therapeutic approaches and predict response."
Continue Paclitaxel After Complete Response in Ovarian Cancer
May 1st 2002MIAMI, Florida-In women with advanced ovarian cancer who achieved a complete response (CR) with a platinum/paclitaxel (Taxol)-based chemotherapy regimen, continuing single-agent paclitaxel for 12 cycles prolonged the duration of progression-free survival, compared with a 3-cycle continuation, Maurie Markman, MD, of the Cleveland Clinic Foundation, said at the 33rd Annual Meeting of the Society of Gynecologic Oncologists (abstract 1).
Breast Cancer Risk Assessment Guidelines Outlined
May 1st 2002MIAMI BEACH, Florida-The Breast Cancer Risk Assessment Working Group is completing work on its consensus guidelines for stratifying patients into risk categories for breast cancer and managing their care accordingly. The model was outlined at the 19th Annual Miami Breast Cancer Conference.
Role of Genomics in Identifying New Targets for Cancer Therapy
May 1st 2002The detailed map of the human genome can potentially transform future cancer therapy by merging genomics with pharmacology, thereby identifying which patients will benefit from specific therapeutic agents. Single-nucleotide polymorphisms (SNPs) provide a valuable tool for this pharmacogenetic approach to cancer therapy.
Early Breast and Ovarian Cancers Detected in Women at High Risk
May 1st 2002When the BRCA1 and BRCA2 genes for breast and ovarian cancers were first identified and a screening blood test became available, a debate ensued as to whether there was an advantage to learning one’s risk. Recently, the value of such testing was demonstrated in a study in women who were followed after being identified as carriers of a BRCA genetic mutation. Researchers at Memorial Sloan-Kettering Cancer Center have provided strong evidence that breast and ovarian cancers can be detected at an early stage in women at highest hereditary risk. Results of the study were published in a recent issue of the Journal of Clinical Oncology (20:1260-1268, 2002).
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Among the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.
Online Breast Cancer Support Groups Beneficial
April 1st 2002WASHINGTON-In recent years online chat rooms and list servers devoted to a vast array of special interests have become a staple of American life. Now a pilot project has shown that an internet support group significantly benefits women coping with breast cancer, said Mitch Golant, PhD, vice president of research and development for The Wellness Community (TWC) National, Santa Monica, California.
New Blood Test for Early Ovarian Cancer in Clinical Trials
April 1st 2002BETHESDA, Maryland-A new proteomics blood test for ovarian cancer (developed by researchers at the joint Food and Drug Administration/National Institutes of Health Clinical Proteomics Program) detected all 50 ovarian cancers in a proof-of-principal trial and is now being validated in a major study of recurrence in stage III/IV ovarian cancer.
‘Awareness Is Not Enough’ to Eliminate Racial Cancer Disparities
April 1st 2002WASHINGTON-Knowledge, research, and education alone will not end the cancer disparities among American populations, said numerous speakers at the opening session of the 8th Biennial Symposium on Minorities, the Medically Underserved, and Cancer, presented by the Intercultural Cancer Council (ICC) and jointly sponsored by Baylor College of Medicine, Houston.
DX-8951f/Gemcitabine Safe, Active in Advanced Solid Tumors
March 1st 2002NEW YORK-The combination of gemcitabine (Gemzar) and a potent, novel topoisomerase-1 inhibitor similar to irinotecan (Camptosar) is safe, has predictable toxicities, and has demonstrated significant antitumor activity in a variety of solid malignancies, according to results of a 70-patient phase I/pharmacokinetic study.
Topotecan/Doxil Studied as Second-Line Ovarian Cancer Therapy
March 1st 2002NEW YORK-Liposomal doxorubicin (Doxil) may be essentially equivalent to topotecan (Hycamtin) as second-line therapy for ovarian cancer, but the combination of the two may have more promise than either agent alone, according to preliminary results of a phase I study.